{
  "schemaVersion": 1,
  "id": "research-372",
  "slug": "372-what-bioequivalence-means-in-a-comparison-of-tesamorelin-formulations",
  "title": "What bioequivalence means in a comparison of tesamorelin formulations",
  "catalogLabel": "Tesamorelin",
  "productCollection": "https://heritagebiolabs.com/research-library/products/tesamorelin",
  "productHandles": [
    "tesamorelin-676",
    "tesamorelin-538",
    "tesamorelin-675"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/tesamorelin-676",
    "https://heritagebiolabs.com/product/tesamorelin-538",
    "https://heritagebiolabs.com/product/tesamorelin-675"
  ],
  "readingFocus": "Methods & identity",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 271,
  "sourceYears": [
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids linked by peptide bonds. When a peptide is made into a drug, formulation can affect how much reaches the circulation. Tesamorelin is a chemically modified 44-residue analogue of growth hormone–releasing hormone. A report published in January 2026 compared how the newer Egrifta WR formulation and the original Egrifta formulation appeared in the blood of healthy adults. [1, 2]",
    "The study used a randomized crossover design in which 36 participants received both formulations in separate periods. Because the same person could contribute measurements under each condition, the analysis could account for some differences that would arise if separate groups received each formulation. The investigators measured the highest observed blood concentration and calculated the area under the concentration curve, a measure of exposure over a specified period. They reported that the formulations met the study's criteria for comparable exposure. [1]",
    "The report is a conference abstract with original study data. The current prescribing information also describes the comparable bioavailability and explains how the clinical evidence from the original formulation supports the labeled product. This is a comparison of systemic exposure under defined study conditions. It does not show that every instruction or presentation for one formulation can be used for another. The label distinguishes Egrifta WR and Egrifta SV, and the study used original Egrifta as its reference. [1, 2]",
    "The volunteers were healthy, and the comparison followed individual exposures. A study of concentration curves can help connect two formulations in a regulatory evaluation. Long-term effectiveness and clinical risk in adults with HIV-associated lipodystrophy are different questions addressed by other parts of the evidence. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Caldji C et al. P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants. Open Forum Infectious Diseases, conference abstract (publication 2026-01-11).",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12791536/"
    },
    {
      "number": 2,
      "citation": "Theratechnologies. EGRIFTA WR- tesamorelin kit. U.S. prescribing information on DailyMed (updated 2026-07-29).",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/372-what-bioequivalence-means-in-a-comparison-of-tesamorelin-formulations",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/372-what-bioequivalence-means-in-a-comparison-of-tesamorelin-formulations.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/372-what-bioequivalence-means-in-a-comparison-of-tesamorelin-formulations.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 075 - Tesamorelin.docx",
    "sourceArticleNumber": 372,
    "contentSha256": "c7fe3bd25f38637268c9a6745dde89bca2beb75d8c910212786644bf29b0e459",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
